KS

HSP90, a heat shock protein, protects cancer cells from chemotherapy. Dr. Vielhauer’s laboratory is developing novel targeted therapy that selectively blocks HSP90 and kills lung cancer cells.

Dr. Sittampalam is determining whether circulating tumor cells can be a useful blood-based tumor marker in untreated patients with extensive-stage small cell lung cancer who are planning to receive chemotherapy. He is also exploring the feasibility of genomic profiling using circulating tumor cells.